PPAR-γAgonists and Their Effects on IGF-I Receptor Signaling: Implications for Cancer

Suppression of Tumor Formation by a Cyclooxygenase-2 Inhibitor and a Peroxisome Proliferator-Activated Receptor   Agonist in an In vivo Mouse Model of Spontaneous Breast Cancer

(2008) A. Mustafa et al.   CLINICAL CANCER RESEARCH

Strain-Specific Effects of Rosiglitazone on Bone Mass, Body Composition, and Serum Insulin-Like Growth Factor-I

(2008) Cheryl L. Ackert-Bicknell et al.   ENDOCRINOLOGY

The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance

(2008) Angelo et al.   Frontiers in Bioscience-Landmark

Clinical Use of PPARγLigands in Cancer

(2008) Jennifer L. Hatton et al.   PPAR Research

Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular Signaling

(2008) Giulia Cantini et al.   PPAR Research

Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies

(2008) Paola Pisani   ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY

Thiazolidinediones: effects on insulin resistance and the cardiovascular system

(2007) C E Quinn et al.   BRITISH JOURNAL OF PHARMACOLOGY